

¹⁸**Abstract**

19 The aim of this study was to evaluate the performance of blood screening 20 strategies in Naggu City, with a focus on serological and nucleic acid testing 21 effectiveness. Analysis of blood donation data from 2017 to 2023 revealed a 22 gradual increase in local blood donation rates, but the rate of unqualified 23 donations remained higher than the national average. Serological performance 24 verification showed good repeatability and precision, but improvements are 25 needed in the accuracy of certain markers. Nucleic acid performance 26 verification demonstrated excellent detection capability for low viral load HBV 27 infections. The conclusion highlights significant progress in the screening 28 strategies of Nagqu City, with the nucleic acid testing system showing 29 outstanding performance. The findings provide valuable insights for blood 30 screening in other high-altitude regions.

³¹**Introduction**

32 Nagqu City, nestled in the northern part of the Tibet Autonomous Region 33 in China on the awe-inspiring Tibetan Plateau, stands as one of the highest 34 cities on Earth, boasting an average elevation of approximately 4,500 meters ³⁵(14,764 feet) above sea level[1]. Its population of 504,838 has transformed the 36 city into a crucial trade and commercial hub, fostering vital connections 37 between various Tibetan regions and neighboring countries[2]. Nevertheless, 38 the delivery of healthcare services, especially blood donation screening, faces 39 formidable challenges due to the city's geographical remoteness, limited 40 infrastructure, and the demanding high-altitude conditions it presents[3].

41 A significant stride towards improving blood donation and healthcare 42 services in the region occurred in 2017 with the establishment of a blood 43 station in Nagqu City. However, this unique city's population demographics 44 and high-altitude environment introduce distinct challenges that demand

2

45 careful consideration for ensuring effective and reliable blood screening and 46 donation procedures^[4-9].

47 Given Nagqu City's remote location and limited infrastructure, the 48 validation and evaluation of laboratory blood testing systems, including 49 serological testing and nucleic acid testing (NAT), assume paramount 50 importance^[10]. This validation entails assessing the accuracy, sensitivity, and 51 specificity of screening methods for detecting infectious diseases and 52 Transfusion-Transmissible Infections (TTIs), such as Hepatitis B virus (HBV), 53 Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV), and Syphilis. 54 Strict adherence to relevant regulations, such as the 'China Blood Bank 55 Quality Management Standards,' 'China Blood Bank Laboratory Quality 56 Management Standards,' and 'China Blood Technical Operating Procedures 57 (2019 edition)' [11-13], ensures the provision of a safe and adequate blood 58 supply to meet the healthcare needs of the local population.

59 In pursuit of evaluating the efficacy of current blood screening strategies, 60 this study meticulously analyzes blood screening results obtained from the 61 Nagqu City blood station laboratory over several years, with a primary focus on 62 comprehending the epidemiological trends of TTIs among the local donor ⁶³population. The profound insights into the prevalence and distribution of TTIs ⁶⁴will facilitate the identification of potential risks and areas for refining screening 65 strategies, thereby ensuring a safe blood supply and mitigating the 66 transmission of infectious diseases[14]. Furthermore, the study scrutinizes the ⁶⁷External Quality Assessment (EQA) results of the Nagqu blood station to 68 assess the laboratory's performance and accuracy in conducting blood 69 screening tests. This rigorous evaluation bolsters the reliability and 70 consistency of screening procedures, while also pinpointing any factors that 71 could impact result quality.

72 Through this comprehensive evaluation of current blood screening

33.33 \sim

73 strategies, the ultimate aim of this study is to refine and optimize the screening 74 protocols, ensuring their unwavering effectiveness and reliability. In doing so, 75 this endeavor seeks to enhance the safety of the blood supply in Nagqu City 76 and potentially engender valuable insights applicable to other high-altitude 77 regions worldwide grappling with similar challenges.

⁷⁸**Materials and methods**

⁷⁹**Sample Collection**

80 A total of 3,585 blood samples were collected from donors in Nagqu City 81 using standard procedures from September 1, 2017 to July 30, 2023. The 82 informed consents were duly obtained from all participants. Furthermore, 83 ethical approval was obtained from the Ethics Committee of the Dalian Blood 84 Center (LL-202202). The screening process involved specific testing 85 equipment for serological and nucleic acid testing.

86 The serological test performance verification (PV) serum panels included 87 HBsAg Serum Panel, HCV Ab Serum Panel, HIV-1 Ab Serum Panel, and TP 88 Ab Serum Panel. Each panel consisted of 20 positive samples, 20 negative 89 samples, 5 analytical sensitivity samples, and a set of precision verification 90 samples. The HIV-1 P24 Serum Panel included 10 positive samples, 20 91 negative samples, 10 analytical sensitivity samples, and a set of precision 92 verification samples. All serum panels were provided by Control Standard Co., 93 Ltd.(Beijing, China). Blood Screening Four-Item Quality Control Samples and 94 Negative Quality Control Samples were provided by Control Standard Co., 95 Ltd.(Beijing, China).

96 The NAT PV serum panels included the NAT Serum Panels C to G 97 (analytical sensitivity verification panels) included a total of 30 samples, with 98 HBV genotype C samples (C2 to C6) having concentrations of 25, 12, 6, 3, and 99 1.5 IU/mL, HCV subtype 2a samples (D2 to D6) having concentrations of 170, ¹⁰⁰85, 40, 20, and 10 IU/mL, HIV genotype CRF07_BC samples (E2 to E6)

de la construcción de la construcc

101 having concentrations of 210, 105, 50, 25, and 12.5 IU/mL, HCV subtype 1b 102 samples (F2 to F6) having concentrations of 140, 70, 35, 17, and 8.5 IU/mL, 103 and HCV subtype 6a samples (G2 to G6) having concentrations of 220, 110, ¹⁰⁴55, 27, and 13 IU/mL. The panel also included 5 negative control samples. The 105 NAT evaluation serum panel A consisted of a total of 46 samples, with each 106 numbered as 3 vials, and each sample having 3 mL. All NAT serum panels 107 were provided by the National Center for Clinical Laboratories (NCCL).

¹⁰⁸**Testing Equipment and Reagents**

109 For serological testing, the ELISA method was used with the Aikang 110 URANUS AE 158 enzyme immunoassay system produced by Shenzhen 111 Aikang Biotechnology Co., Ltd. For nucleic acid testing, the DaAn Gene 112 DA3500S Nucleic Acid Extraction System from Guangzhou, China, and the 113 Aoyu AGS4800 PCR Amplification System from Hangzhou, China, were 114 employed.

115 Various diagnostic kits were used for specific tests:

116 HBsAg (Hepatitis B Surface Antigen) diagnostic kit: InTec Products, Inc.

117 (Xiamen, China), WANTAI BioPharm, Co., Ltd. (Beijing, China)

118 HCV (Hepatitis C Virus) antibody diagnostic kit: WANTAI BioPharm, Co.,

119 Ltd. (Beijing, China), Livzon Pharmaceutical Group Inc. (Zhuhai, China)

120 HIV (Human Immunodeficiency Virus) antibody diagnostic kit: WANTAI 121 BioPharm, Co., Ltd. (Beijing, China), Livzon Pharmaceutical Group Inc.

122 (Zhuhai, China)

123 Treponema pallidum (Syphilis) antibody diagnostic kit: InTec Products, Inc.

124 (Xiamen, China), WANTAI BioPharm, Co., Ltd. (Beijing, China)

125 Nucleic Acid Extraction: DaAn Blood Screening HBV, HCV, and HIV-1

126 Virus Nucleic Acid Test Kit from DAAN Gene (Guangzhou, China)

127 All testing reagents and kits were selected based on their suitability for 128 detecting specific markers and pathogens related to Hepatitis B, Hepatitis C,

129 HIV, and syphilis. The testing procedures and methods followed the 130 instructions provided by the manufacturers.

¹³¹**Screening Strategy**

132 The serological markers were tested using different reagents, and each 133 marker was tested once. Single-Side Reactivity: If a single-side reagent 134 reaction was observed, a necessary repeat test was conducted to confirm the 135 result. If the repeated test still showed reactivity, the sample was considered 136 unqualified for single-side reactivity. Dual-Side Reactivity: If both side reagents 137 showed reactivity simultaneously, the sample was considered unqualified for 138 both sides. A non-reactive result in the nucleic acid test was considered 139 qualified, while a reactive result was deemed unqualified.

140 Both serological testing and NAT were conducted simultaneously, and 141 blood donations with qualified results for both tests were released.

¹⁴²**Serological Test Validation Procedure**

¹⁴³**Reproducibility**

144 Each Blood Screening Four-Item Quality Control Sample and Blood 145 Screening Negative Quality Control Sample were tested 10 times. All 20 test 146 results can not appear more than 1 negative/positive control does not meet the 147 manufacturer's requirements.

¹⁴⁸**Precision**

149 The precision verification samples of PV serum panels was tested within 150 one day. The CV of variation of intra-batch imprecision should be less than 151 15%.

¹⁵²**Sensitivity and Specificity**

153 The PV serum panels were applied and tested according to the 154 instructions. All samples within the blood screening panel were tested within 155 one day. The sensitivity and specificity are calculated based on the detection 156 results.

¹⁵⁷**Compliance**

158 The test results of laboratory samples participating in NCCL were 159 analyzed, the consistency of laboratory test results and NCCL target value 160 results was compared, and the coincidence rate of detection method was 161 calculated.

¹⁶²**Determination of Limit of Detection (LOD)**

- 163 Sensitivity samples from PV serum panels were subjected to serial
- 164 dilution. For each individual assay, three different concentrations were
- 165 prepared and subjected to 20 repeated tests. The LOD for each assay was
- 166 calculated as the lowest concentration at which 95% of the results yielded a
- 167 Signal-to-Cut-off ratio (S/CO) ≥1.

¹⁶⁸**NAT Validation Procedure**

¹⁶⁹**Analytical Sensitivity**

170 The laboratory evaluated the analytical sensitivity using NAT Serum 171 Panels C to G provided by NCCL. The samples covered the minimum 172 detection limits declared in the reagent instructions (HBV/HCV/HIV \leq 100 173 IU/mL). Before testing, the samples were thawed at room temperature and 174 mixed thoroughly by vortexing for 30 seconds or inverting 30 times. Each 175 sensitivity verification panel was tested over three days, with each 176 concentration tested in at least 6 replicates per day, totaling no less than 20 177 replicates over the three days. SPSS 20.0 was used for PROBIT analysis to 178 assess the LOD and the two-sided 95% CI for each virus.

¹⁷⁹**Precision**

180 The laboratory assessed precision using standard materials with 181 concentrations less than 3 times the LOD for HBV DNA(25 IU/mL), HCV RNA ¹⁸²(170 IU/mL), HIV-1 RNA (105 IU/mL) and negative controls provided by the 183 NCCL. Each material was tested 20 times, and the results were collected to 184 calculate the system's precision.

7

¹⁸⁵**Cross-Contamination**

186 To evaluate cross-contamination, five positive standard materials (C2 to 187 G2) from the Analytical Sensitivity Serum Panel were placed together with five 188 negative standard materials from the NAT Serum Panels in a single-test mode 189 using the sample rack. The laboratory analyzed the detection results of both 190 positive and negative standard materials to assess any cross-contamination.

¹⁹¹**Consistency**

192 The laboratory analyzed the test results of laboratory samples 193 participating in the NCCL EQA. The coincidence rate between the laboratory's 194 test results and the NCCL results was calculated to evaluate the system's 195 consistency.

¹⁹⁶**Detecting low viral load HBV infections**

197 46 samples with low concentration of HBV DNA from NAT Serum A 198 provided by the NCCL. The samples were remelted at room temperature 199 before detection, swirled for 30 seconds or reversed for 30 times, thoroughly 200 mixed, and centrifuged for 1000-1500g for 5 minutes. All samples were tested 201 by single-sample test, the first test was only once, and the second test was 202 double-hole retest.

²⁰³**Results**

²⁰⁴**Innovations and Challenges in Blood Donation**

205 Despite facing geographical remoteness and limited infrastructure, Nagqu 206 City has made remarkable efforts to overcome challenges in healthcare 207 delivery and blood donation. Innovations in healthcare include the 208 implementation of telemedicine, providing remote consultations and medical 209 services, along with the deployment of mobile healthcare units to extend 210 essential care to remote communities. Community education and engagement 211 have played a pivotal role in promoting blood donation, with awareness 212 campaigns and blood drives leading to a significant increase in donors. As

213 indicated in Table 1, these initiatives have contributed to an overall rise in 214 blood donations over the years, showcasing the active participation of the local 215 population in blood donation. However, despite progress in healthcare and 216 blood donation, challenges persist. Factors such as religious beliefs among 217 ethnic minorities and seasonal weather conditions contribute to blood 218 shortages in Nagqu City. Severe weather conditions from October to April, 219 including snowstorms, windstorms, hailstorms, and flooding, significantly 220 impact the accessibility and availability of blood donations. These unique 221 challenges necessitate further efforts to address the issue of blood shortages 222 while considering the specific religious and climatic factors in the region.

223 Table 1 and Fig 1 provide data on the number and rate of unqualified 224 donations over the years, demonstrating the effectiveness of serological 225 testing strategies. The rate of unqualified donations has generally decreased 226 over time, indicating an improvement in the effectiveness of serological testing 227 strategies. However, when compared to the national average rates from the 228 2021 National Research on Blood Screening, Nagqu City's rates of unqualified 229 donations for various blood screening markers consistently exceed the 230 national average. This highlights the challenge of ensuring a safe and 231 adequate blood supply in Nagqu City, given the high prevalence of TTIs, 232 particularly HBV.

- 233
234
-

²³⁴**Table1. Number of Donations and Number (Rate) unqualified Donations** ²³⁵**in Nagqu City from 2017 to 2023**

²⁴³**Performance Verification of Blood Screening**

244 To further analyze the performance of blood screening strategies in 245 Nagqu City, we conducted performance verification for both serological and 246 nucleic acid testing procedures. The results, presented in Tables 2, 3 and 4, 247 provide valuable insights into the reliability and accuracy of the testing 248 methods.

249 Table 2 demonstrates the Serological Testing Performance Verification for 250 TTIs in Nagqu City. The results indicate reliable repeatability, with all markers 251 achieving 100% consistency in repeated testing. HIV p24 Ag (WANTAI) and ²⁵²TP Ab (WANTAI) showed higher precision with CV values of 4.04% and 4.3%, 253 respectively, while HCV Ab (Livzon) and HBsAg (InTec) exhibited higher CV 254 values of 14.30% and 13.87%, but still below the acceptable limit of 15%. 255 Sensitivity and specificity were 100% for all markers. The EQA activities in 256 2021 and 2022 involved multiple assessments, and all testing items, including 257 HBsAg, HCV Ab, HIV-1 Ab, and TP Ab, achieved 100% compliance, indicating 258 high levels of accuracy and precision in the laboratory's testing procedures 259 during these years.

260
261

²⁶¹**Table 2. Serological Testing Performance Verification for TTIs in Nagqu** 262 City

263 Note: "-" indicating that the test was not performed.
264

265 Table 3 and Fig 2 present the LOD for serological blood screening 266 markers. According to the results, the LOD for HBsAg detection was 0.2 IU/mL 267 for both InTec and WANTAI. For HCV Ab detection, WANTAI and Livzon 268 achieved LODs of 0.025 NCU/mL and 0.013 NCU/mL, respectively. The LOD 269 for HIV-1 Ab detection with both WANTAI and Livzon was 0.25 NCU/mL. In the 270 case of HIV-1 p24 detection, the LODs were 1.25 U/mL and 2.5 U/mL for 271 WANTAI and Livzon, respectively. Notably, for TP Ab detection, both InTec 272 and WANTAI exhibited relatively low LODs at 1.5 mIU/mL.

- 273
- 273

²⁷⁴**Table 3. Serological Testing LOD for TTIs in Nagqu City**

 276 considered as a detectable result.
 277

²⁷⁸**Fig 2. Detection Limits of Serological Blood Screening Markers in Nagqu City**

280 Table 4 presents the Performance Verification of NAT for TTIs in Nagqu 281 City. The results demonstrate reliable analytical sensitivity, with LODs within 282 the declared limits for HBV, HCV, and HIV detection. The precision was 283 satisfactory for most markers, with CV values below 5%, indicating good 284 repeatability. The system exhibited excellent specificity, as 285 cross-contamination was not observed. Additionally, the consistency analysis 286 showed a 100% coincidence rate between the laboratory's results and the 287 NCCL results, confirming the accuracy and reliability of the nucleic acid testing 288 system used in Nagqu City.

 12

²⁹⁰**Table 4. Performance Verification of NAT for TTIs in Nagqu City**

²⁹²**Evaluation of Blood Screening Strategies**

293 The evaluation of blood screening strategies aimed to assess the 294 performance and suitability of the Nagqu NAT system for nucleic acid 295 screening strategies. As shown in Table 5, all the samples from Serum Panel 296 A were tested negative for HBsAg using chemiluminescent immunoassay. 297 These samples were confirmed by the NCCL to be HBV DNA low 298 concentration samples. Among them, 18 samples showed reactive results in 299 the Roche NAT system, of which 8 samples were also reactive in our initial 300 screening, resulting in a screening positive concordance rate of 44.44%. In the 301 confirmatory retesting, 14 samples remained reactive, resulting in a 302 confirmatory positive concordance rate of 77.78%. Similarly, in the Haoyuan 303 NAT system, 22 samples showed reactive results, with 13 samples being 304 reactive in our initial screening, yielding a screening positive concordance rate 305 of 59.09%. In the confirmatory retesting, 13 samples remained reactive, 306 resulting in a confirmatory positive concordance rate of 59.09%. Among the 38 307 samples that tested positive for HBcAb in serological testing, our initial 308 screening yielded a detection rate of 47.37% (18/38), while the confirmatory 309 retesting had a detection rate of 68.57% (24/35). Three samples were not 310 retested due to insufficient sample volume. The results indicate the

 \sim

311 performance of the Nagqu NAT system in detecting HBV DNA and its 312 concordance with other NAT systems.

313 The results demonstrate the effectiveness of the nucleic acid testing 314 system, particularly in detecting low viral load HBV infections. The system's 315 adoption has proven to be more efficient in preventing the transmission of HBV 316 through blood transfusions in high-prevalence regions like Naggu City. The 317 findings underscore the importance of NAT in maintaining a safe blood supply 318 and reducing the risk of transfusion-transmitted HBV infections. Moreover, the 319 testing strategy is also cost-effective and suitable for high-altitude regions with 320 low donation volume, using a single-test mode. Despite the challenges posed 321 by the high-altitude and dry climate of Nagqu City, the blood screening 322 procedures have demonstrated minimal differences compared to the plains 323 regions. The system exhibited excellent stability and accuracy, ensuring 324 reliable blood screening results even under such environmental conditions.

³²⁶**Table 5. Results of s Serum Panel A of HBV DNA low viral load samples**

³²⁷**tested in different NAT systems**

328 Note: The sample IDs used in this study were strictly internal and confidential, known only within the research group.
329 MPX: cobas® TagScreen MPX Test Kit (v2.0) tested by Roche cobas s 201system. Haoyuan: Haoyuan B

³²⁹MPX: cobas® TaqScreen MPX Test Kit (v2.0) tested by Roche cobas s 201system. Haoyuan: Haoyuan Biotech NAT

330 Kit for HBV/HCV/HIV -1 ((Real-time PCR) tested by Haoyuan ChiTaS BSS1200 NAT system. R: Reactive. NR:
331 Non-reactive. N/A: Untested. Parallel NAT system detection results data provided by NCCL.

Non-reactive. N/A: Untested. Parallel NAT system detection results data provided by NCCL.

³³²**Discussion**

333 This study aimed to investigate the blood screening strategies in Nagqu 334 City, Tibet, with a specific emphasis on the performance of serological and 335 nucleic acid testing. Despite encountering distinctive challenges of

336 geographical remoteness, high-altitude hypoxia, and a dry climate, valuable 337 insights can be gleaned from the analysis of blood screening outcomes.

338 The effectiveness and reliability of blood screening have demonstrated 339 continuous improvement, as evidenced by a declining trend in the rate of 340 unqualified donations over time, indicating the enhanced effectiveness of 341 screening strategies (Table 1). However, it is crucial to note that Nagqu City's 342 rates of unqualified donations for various markers still exceed the national 343 average. The majority (58.13%, 143/246) of the unqualified blood donations 344 detected in laboratories were attributed to failing the ALT screening, which 345 may be related to the donors' liver function. However, it is more likely 346 associated with unhealthy lifestyle habits, such as poor diet, alcohol 347 consumption, and medication use. To ensure the effective utilization of blood 348 resources, the importance of pre-donation screening for ALT should be 349 emphasized. Notably, positive results for HBV were the primary reason for 350 donor deferral in TTIs tests, with 9.76% (24/246) attributed to HBsAg and 351 11.38% (28/246) to HBV-DNA. Additionally, Treponema pallidum (TP), which 352 causes syphilis, accounted for a significant proportion (15.85%, 39/246) of 353 unqualified donations. These findings align with prevailing trends observed in 354 other high-altitude regions of the Qinghai-Tibet Plateau but are considered 355 considerably high when compared to other developing countries[15-18]. 356 Moreover, it is essential to acknowledge that the prevalence of HBV infection 357 remains alarmingly high in China, with approximately 100 million people 358 suffering from chronic HBV infection[19]. The high prevalence of HBV and 359 other infectious markers in the blood donor pool in this region emphasizes the 360 importance of stringent quality management and individual donation nucleic 361 acid detection protocols in blood banks to ensure blood safety and prevent 362 potential HBV transfusion transmission[20-22]. Efforts should be directed 363 towards implementing effective measures to reduce the number of unqualified

364 donations, continuing to monitor the local TTIs' prevalence trends, and 365 enhancing overall blood safety in this geographically challenging area[23, 24]. ³⁶⁶By addressing these challenges and implementing targeted interventions, the 367 blood screening system in Nagqu City can further improve its effectiveness 368 and contribute to safer and more reliable blood donations.

369 The challenging high-altitude, oxygen-deficient, and dry climate conditions 370 in Nagqu indeed present unique obstacles to the blood screening process. 371 However, the results of the performance verification (as detailed in Tables 2, 3 372 and 4) illustrate the reliability and accuracy of both serological and nucleic acid 373 testing procedures in overcoming these challenges. Across all markers, there 374 is a consistent demonstration of high levels of consistency, reproducibility, 375 sensitivity, and specificity, ensuring that results are both reliable and precise. 376 One of the critical parameters in evaluating the effectiveness and sensitivity of 377 diagnostic assays is the LOD for serological blood screening markers. This 378 study undertook a comprehensive investigation into the LODs for various 379 bloodborne pathogens, encompassing HBsAg, HCV Ab, HIV-1 Ab, HIV-1 p24, 380 and TP Ab, using different test reagents. Remarkably, the observed LOD of 381 0.2 IU/mL for HBsAg detection in Nagqu City stands out, as it is significantly 382 lower than the LODs reported in the literature for domestically produced test 383 reagents. Typically, these reported LODs are around 0.6-1 IU/mL [25, 26]. This 384 remarkable increase in sensitivity is particularly advantageous, especially in 385 regions where early detection of hepatitis B infection is of paramount 386 importance due to the high prevalence of this disease. The findings shed light 387 on the performance and capabilities of these assays in Nagqu City, Tibet, 388 under challenging environmental conditions.

389 In this study, the NAT system displayed excellent capability in detecting 390 HBV DNA, which is particularly beneficial in high-altitude regions with a high 391 prevalence of HBV transmission[27]. The adoption of the NAT system

 177 and 177

392 effectively detects low viral load HBV infections, minimizing the risk of HBV 393 transmission through blood transfusions[28]. This finding is crucial in reducing 394 the risk of transfusion-transmitted HBV infections and emphasizes the 395 significance of NAT in maintaining a safe blood supply. Other regions can 396 learn from Nagqu City's NAT strategies to strengthen monitoring and 397 prevention measures for low viral load infections, further enhancing transfusion 398 safety.

399 The research findings indicate minimal differences in the blood screening 400 process between Nagqu and plains regions in China[29-33]. Furthermore, the 401 system demonstrated exceptional stability and accuracy, signifying significant 402 progress in adapting to the high-altitude and dry conditions. The adaptability 403 and performance of the blood screening system in challenging environmental 404 conditions are commendable, highlighting the commitment of healthcare 405 professionals in Nagqu City to ensuring safe and reliable blood donations. 406 Despite the unique challenges posed by the high-altitude and dry climate, the 407 blood screening process in Nagqu City has demonstrated remarkable 408 effectiveness and reliability. The successful implementation of the NAT system 409 and the consistent performance of serological testing underscore the 410 commitment to maintaining a safe blood supply and preventing 411 transfusion-transmitted infections. These research findings not only benefit 412 Nagqu City but also provide valuable insights and practical guidance for other 413 high-altitude regions facing similar challenges in blood screening and 414 transfusion safety.

415 **In conclusion, this study provides a comprehensive evaluation of blood** 416 screening strategies in Nagqu City, demonstrating the effectiveness and 417 reliability of the current procedures. The research also offers valuable insights 418 and practical implications for other geographically remote and high-altitude 419 regions, particularly in nucleic acid testing. Through continuous improvement

 $\overline{18}$

420 and optimization strategies, we can further enhance the quality of blood 421 screening, ensure transfusion safety, and provide beneficial experiences and 422 guidance for blood screening in similar regions. This study fills gaps in 423 knowledge and offers important references and practical value for improving 424 blood screening and enhancing transfusion safety in geographically remote 425 regions. Future research should explore blood screening strategies adapted to 426 high-altitude and dry conditions to provide broader significance for other 427 geographically remote regions.

⁴²⁸**Acknowledgments**

429 We extend our heartfelt gratitude to the National Center for Clinical 430 Laboratories their invaluable support, including their high regard for this study, 431 provision of panel samples, and technical assistance. Our sincere appreciation 432 goes to the Tibetan government for their multifaceted support. Special 433 recognition is due to the dedicated staff members of the blood bank 434 laboratories, whose unwavering support during the experiments is highly 435 commendable.

⁴³⁷**Author Contributions**

- 438 Conceptualization: Yaxin Fan
- 439 Data curation and analysis: Liang Zang, Lei Zhou, Ji Duo
- 440 Investigation: Liang Zang, Lei Zhou, Yaxin Fan, Xiaohua Liang, Ji Duo
- 441 Methodology: Liang Zang, Lei Zhou, Yaxin Fan, Xiaohua Liang, Ji Duo, Hao
- 442 Lin, Rui Bai, Mei Yang, Chao Dan

- 443 Project Administration: Liang Zang, Yaxin Fan, Xiaohua Liang
- 444 Resources: Liang Zang, Yaxin Fan
- 445 Supervision: Yaxin Fan, Xiaohua Liang
- 446 Writing: Liang Zang
- 447 Writing Review & Editing: Liang Zang, Lei Zhou, Yaxin Fan, Xiaohua Liang, Ji
- 448 Duo, Hao Lin, Rui Bai, Mei Yang, Chao Dan.

⁴⁵⁰**References**

- 451 1. Nagqu overview. Nagqu City People's Government. Available online:
- 452 http://www.naqu.gov.cn/nqsrmzf/c100075/list_tt.shtml (accessed on 28 July
- ⁴⁵³2023).
- 454 2. Figures on 2020 Population Census of China. Seventh National Census
- 455 Leading Group Office of The State Council. China Statistics Press. ISBN
- 456 978-7-5037-9506-0.
457 3. Foggin PM. Torra
- 457 3. Foggin PM, Torrance ME, Dorje D, Xuri W, Marc Foggin J, Torrance J.
458 Assessment of the health status and risk factors of Kham Tibetan pastora
- 458 Assessment of the health status and risk factors of Kham Tibetan pastoralists
459 in the alpine grasslands of the Tibetan plateau. Soc Sci Med. 2006
- 459 in the alpine grasslands of the Tibetan plateau. *Soc Sci Med*. 2006
460 Nov:63(9):2512-32. https://doi.org/10.1016/j.socscimed.2006.06.01
- 460 Nov;63(9):2512-32. <u>https://doi.org/10.1016/j.socscimed.2006.06.018</u> PMID:
461 16891047.
- ⁴⁶¹16891047.
- 4. Lang M., Bilo G., Caravita S., Parati G. Blood pressure and high altitude:
- ⁴⁶³Physiological response and clinical management. *Medwave*. 2021;21:e8194.
- ⁴⁶⁴http://doi.org/10.5867/medwave.2021.04.8194 PMID: 34037579.
- 465 5. Huamaní C, Sarmiento W, Cordova-Heredia G, Cruz-Huanca L,
- 466 Damian-Saavedra P, Antonio D. Prediction of blood viscosity based on usual
- 467 hematological parameters in a clinically healthy population living in a

- ⁴⁶⁸high-altitude city. *High Alt Med Biol*. 2022 Mar;23(1):78-84.
- ⁴⁶⁹https://doi.org/10.1089/ham.2021.0165 PMID: 35271375.
- 470 6. Wang Y, Wang H, Chen Y, Xu N, Lee W, Lam WK. Pulmonary capacity,
- 471 blood composition and metabolism among coal mine workers in high- and
- ⁴⁷²low-altitude aboveground and underground workplaces. *Int J Environ Res*
- ⁴⁷³*Public Health*. 2022 Jul 7;19(14):8295. https://doi.org/10.3390/ijerph19148295
- 474 PMCID: PMC9318192.
- 475 7. MacNutt MJ, Sheel AW. Performance of evacuated blood collection tubes at
- ⁴⁷⁶high altitude. *High Alt Med Biol*. 2008 Fall;9(3):235-7.
- ⁴⁷⁷https://doi.org/10.1089/ham.2008.1027 PMID: 18800961.
- ⁴⁷⁸8. Chandramoorthy HC, Bajunaid AM, Kariri HN, Al-Hakami A, Sham AA,
- 479 Al-Shahrani MBS, et al. Feasibility of cord blood bank in high altitude Abha:
- ⁴⁸⁰preclinical impacts. *Cell Tissue Bank*. 2018 Sep;19(3):413-422.
- 481 https://doi.org/10.1007/s10561-018-9687-0 PMID: 29460118.
- 482 9. Luo X, Feng L, Bai X, Zhu J, Zhao G, Wu M, et al. Continuous changes in
- 483 biological levels of complete blood count in a high altitude area of China.
- ⁴⁸⁴*SAGE Open Med*. 2020 Jun 13;8:2050312120931334.
- ⁴⁸⁵https://doi.org/10.1177%2F2050312120931334 PMID: 32587693.
- ⁴⁸⁶10. Andriessen JW, Breard M, Briggs L, Butch S, Distler P, Georgsen J, et al.
- 487 International society for blood transfusion guidelines for validation of
- 488 automated systems in blood establishments. Vox Sang. 2022
- 489 Dec;117(12):1420-45. https://doi.org/10.1111/vox.13332 PMID: 36285799.
- ⁴⁹⁰11. National Health Commission of the People's Republic of China. *China*
- ⁴⁹¹*Blood Bank Quality Management Standards*. April 25, 2006.
- ⁴⁹²12. National Health Commission of the People's Republic of China. *China*
- ⁴⁹³*Blood Bank Laboratory Quality Management Standards*. May 9, 2006.
- ⁴⁹⁴13. National Health Commission of the People's Republic of China. *China*
- ⁴⁹⁵*Blood Technical Operating Procedures*. May 8, 2019.

- 496 14. Folléa G, Garraud O, Tiberghien P. Blood transfusion: the challenges for
- 497 tomorrow? *Presse Med.* 2015 Feb;44(2):227-32.
- 498 https://doi.org/10.1016/j.lpm.2014.06.038 PMID: 25578549.
- 499 15. Sun P, Zhu L, Ma L, Li C, Wang Z, Zhang R, et al. Blood service in a region
- 500 of China's Qinghai-Tibetan plateau. Healthcare (Basel). 2023 Jul
- ⁵⁰¹5;11(13):1944. http://doi.org/10.3390/healthcare11131944 PMID: 37444778;
- 502 PMCID: PMC10341248.
- ⁵⁰³16. Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of
- 504 transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
- ⁵⁰⁵*Transfusion*. 2007 Mar;47(3):529-39.
- 506 https://doi.org/10.1111/j.1537-2995.2006.01146.x PMID: 17319836.
- 507 17. Xuerong Yu, Weiyun Chen, Zhong Liu, Yuguang Huang. Safety and
- ⁵⁰⁸current status of blood transfusion in China: an update. *Lancet Haematol*. 2016
- 509 Feb;3(2):e60-2. https://doi.org/10.1016/S2352-3026(16)00010-7 PMID:
- ⁵¹⁰26853643.
- 511 18. Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and
- 512 trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C
- 513 virus among blood donors in Iran, 2004 through 2007. *Transfusion*. 2009
- 514 Oct;49(10):2214-20. https://doi.org/10.1111/j.1537-2995.2009.02245.x PMID:
- ⁵¹⁵19527477.
- 516 19. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the
- 517 impact of hepatitis B vaccination among children born during 1992-2005 in
- ⁵¹⁸China. *J Infect Dis*. 2009 Jul 1;200(1):39-47. https://doi.org/10.1086/599332
- 519 PMID: 19469708.
- 520 20. El Ekiaby M, Lelie N, Allain JP. Nucleic acid testing (NAT) in high
- 521 prevalence-low resource settings. *Biologicals*. 2010 Jan;38(1):59-64.
- ⁵²²https://doi.org/10.1016/j.biologicals.2009.10.015 PMID: 20079664.

- 523 21. Chang L, Zhao J, Guo F, Ji H, Zhang L, Jiang X, et al. Demographic
- 524 characteristics of transfusion-transmitted infections among blood donors in
- ⁵²⁵China. *BMC Infect Dis*. 2019 Jun;19(1):514.
- 526 https://doi.org/10.1186/s12879-019-4044-x PMID: 31185990.
- 527 22. Abdella S, Moshago Berheto T, Tolera G, Belete W, Deressa T, Feleke A,
- 528 et al. Sero-prevalence of transfusion transmittable infections: HIV, Hepatitis B,
- 529 C and Treponema pallidum and associated factors among blood donors in
- ⁵³⁰Ethiopia: A retrospective study. *PLoS One*. 2020 Oct 29;15(10):e0241086.
- 531 https://doi.org/10.1371/journal.pone.0241086 PMID: 33119668.
- 532 23. Raykar NP, Makin J, Khajanchi M, Olayo B, Munoz Valencia A, Roy N, et
- 533 al. Assessing the global burden of hemorrhage: The global blood supply,
- 534 deficits, and potential solutions. *SAGE Open Med.* 2021 Nov
- ⁵³⁵10;9:20503121211054995. https://doi.org/10.1177/20503121211054995
- 536 PMID: 34790356.
- 537 24. Aneke JC, Okocha CE. Blood transfusion safety; current status and
- 538 challenges in Nigeria. Asian J Transfus Sci. 2017 Jan-Jun;11(1):1-5.
- 539 https://doi.org/10.4103/0973-6247.200781 PMID: 28316432.
- 540 25. Yihe Xiong. Application of two domestic HBsAg ELISA diagnostic reagents
- 541 in blood screening. Jilin Medical Journal. 2012;(7):1398-9. [in Chinese]
- 542 26. Lianghua Wang, Xuqun Wu, Ziqian Bao, Yunlong Chen, Xianlin Ye,
- 543 Guifang Shang, et al. Comparison of HBsAg retest results by different ELISA
- 544 reagents. *Chin J Blood Transfusion*. 2007;(2):124-5. [in Chinese]
- 545 27. Wang Y, Wu Z, Yin YH, Rao SQ, Liu B, Huang XQ, et al. Blood service in
- ⁵⁴⁶the Tibetan regions of Garzê and Aba, China: a longitudinal survey. *Transfus*
- ⁵⁴⁷*Med*. 2017 Dec;27(6):408-12. https://doi.org/10.1111/tme.12468 PMID:
- ⁵⁴⁸28944508.
- 549 28. Chen J, Ou-Yang J, Xie G, Liang H, Fan Y, Gao R, et al. Problems and
- 550 challenges: development of blood transfusion services in Mainland China

- 551 within the context of health-care system reform. Transfus Med. 2019 Aug;
- ⁵⁵²29(4):253-61. https://doi.org/10.1111/tme.12618 PMID: 31359545.
- ⁵⁵³29. Xiaoyan Han, Maili Zhang, Xu Feng, Miaomiao Xu. Performance
- ⁵⁵⁴verification of nucleic acid testing project based on ISO 15189 . *Chin J Blood*
- ⁵⁵⁵*Transfusion.* 2022 Jan;35(01):95-8. [in Chinese]
- 556 30. Li Zhan, Wenjie Yang, Zhigiang Chen, Zhangping Fan. Performance
- 557 evaluation of a domestic blood nucleic acid detection system. *J Mol Diagn*
- ⁵⁵⁸*Ther*. 2023 Mar;15(3):442-5. http://doi.org/10.19930/j.cnki.jmdt.2023.03.003
- 559 31. Kai Chen, Yinghui Wang, Zhifeng Yuan. Discussion on performance
- 560 validation of nucleic acid test system in blood station. *J Clin Hematol (China)*,
- 561 2022;35 (8) : 584-91. [in Chinese]
- 562 32. Junying Li, Yifang Wang, Wenchao Ge, Xu Wang, Jianhua Fang. The
- 563 performance validation of a nucleic acid test system before blood screening.
- ⁵⁶⁴*Chin J Blood Transfusion*. 2019 Jan;32(1):73-5. [in Chinese]
- ⁵⁶⁵33. Runkui Wei, Lin Yu, Shaobin Chen, Miaoling Deng, Jingwen Chen, Ziyi He.
- 566 Performance verification of an individual donation nucleic acid detection
- 567 system for blood. *Chin J Blood Transfusion*. 2022 Apr;35(4):449-52. [in
- 568 Chinese]